COLORADO SPRINGS, Colo., The Spectranetics Corporation (NASDAQ:SPNC) today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance of its peripheral atherectomy product, the ...
According to a recent press release, Colorado Springs-based Spectranetics announced that it has received FDA 510(k) clearance for its Turbo-Power™ Laser Atherectomy Catheter, a peripheral atherectomy ...
The Spectranetics Corporation announced receipt of FDA 510(k) clearance of their peripheral atherectomy products, Turbo-Tandem and Turbo Elite, for the treatment of in-stent restenosis, or ISR. "FDA ...
Spectranetics to Initiate Landmark Randomized Study of Laser Treatment for Peripheral Artery Disease
The study will compare the safety and efficacy of excimer laser atherectomy utilizing the Spectranetics’ Turbo-Tandem and Turbo Elite products in conjunction with balloon angioplasty, with that of ...
The problem of peripheral in-stent restenosis (ISR) remains a major problem for clinicians and there is currently no FDA-cleared or approved device to treat this growing patient population. There are ...
Please provide your email address to receive an email when new articles are posted on . Spectranetics, which makes balloons and catheters for peripheral and coronary intervention, announced that it ...
Royal Phillips NV is set to acquire Spectranetics Corp. for €1.9 billion ($2.2 billion). The proposed acquisition is the latest in a string of efforts the Amsterdam, the Netherlands-based company has ...
Spectranetics To Initiate Landmark Randomized Study Of Laser Treatment For Peripheral Artery Disease
Spectranetics Corporation today announced that it plans to initiate the EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results